Q32 Bio, formerly known as Admirx, is a biotechnology company developing therapies targeting powerful regulators of the innate and adaptive immune systems.
Q32 Bio's goal is to re-balancing the immune system in severe autoimmune and inflammatory diseases.
Q32 Bio was founded in 2017 by Michael Broxson and Shelia Violette. The company is headquartered in Cambridge, Massachusetts.
Q32 Bio's lead program in innate immunity, ADX-097, is based on a groundbreaking platform providing tissue-targeted regulation of the complement system. It is focused on the IL-7R pathway and complement system, address immune dysregulation to help patients take back control of their lives.
Q32 Bio's proprietary and unique platform has yielded a pipeline of novel protein therapeutics that provide potent inhibition of complement in diseased tissues without long-term systemic blockade – a key differentiator versus current complement therapeutics.
Q32 Bio has raised $46M in Series A round of funding on May 27, 2020. The investment was led by Atlas Venture included OrbiMed Advisors, Abingworth, and Sanofi Ventures.